在正在进行的临床试验中新增研究组时的统计学考量:潜力与注意事项
本文围绕平台试验中新增研究组这一灵活设计,讨论由此产生的统计学问题,包括新增干预的推断、对照组变更、不同组间患者入选标准差异以及操作偏倚等,并总结近期方法学进展与可增强设计与分析稳健性的途径,最后评述平台试验在II期与III期、公共资助与企业资助情境下的适用性。
要点
- 新增研究组需提前考虑统计学推断的稳健性。
- 变更对照组、各组入选标准差异可增加设计与分析复杂性。
- 揭示部分试验结果可能引入操作偏倚,需加以管理。
核心结论
- 平台试验为提升干预评估效率提供了很大机会,虽存在若干统计学问题,但已有多种方法可实现稳健而高效的设计与分析。
研究设计与样本
- 本文为方法学讨论类文章,阐述在正在进行的临床研究中允许新增研究干预所带来的不同统计学考量,并介绍近期方法学进展与可增强稳健推断的设计和分析途径。
主要发现
- 文章讨论了新增研究组相关的统计学考量,涉及变更对照组的影响、不同组间患者入选资格可能使试验设计与分析复杂化,以及揭示部分试验结果时可能产生操作偏倚。
临床怎么用
- 在平台试验中新增研究组时,应预先评估对照组变更、各组入选标准差异与操作偏倚等统计学问题,并采用可增强稳健推断的设计与分析方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Platform trials improve the efficiency of the drug development process through flexible features such as adding and dropping arms as evidence emerges. The benefits and practical challenges of implementing novel trial designs have been discussed widely in the literature, yet less consideration has been given to the statistical implications of adding arms. MAIN: We explain different statistical considerations that arise from allowing new research interventions to be added in for ongoing studies. We present recent methodology development on addressing these issues and illustrate design and analysis approaches that might be enhanced to provide robust inference from platform trials. We also discuss the implication of changing the control arm, how patient eligibility for different arms may complicate the trial design and analysis, and how operational bias may arise when revealing some results of the trials. Lastly, we comment on the appropriateness and the application of platform trials in phase II and phase III settings, as well as publicly versus industry-funded trials. CONCLUSION: Platform trials provide great opportunities for improving the efficiency of evaluating interventions. Although several statistical issues are present, there are a range of methods available that allow robust and efficient design and analysis of these trials.
引用
- Lee KM, Brown LC, Jaki T, et al. Statistical consideration when adding new arms to ongoing clinical trials: the potentials and the caveats. Trials. 2021. PMID: 33691748. doi:10.1186/s13063-021-05150-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。